Surrogates, meta‐analysis and cost‐effectiveness modelling: a combined analytic approach

Neil Hawkins, Gerry Richardson, Alex J Sutton, Nicola J Cooper, Chris Griffiths, Anne Rogers and Peter Bower

Health Economics, 2012, vol. 21, issue 6, 742-756

Abstract: Estimates of cost‐effectiveness analyses are typically obtained either directly from ‘trial’ based analyses or indirectly via surrogate endpoints in ‘model’ based analyses. Data from clinical trials that include both surrogate and final endpoints can be used in a joint analysis that combines these two approaches. This joint approach allows the inclusion of information regarding the effects of treatment on surrogate endpoints while relaxing the strong assumption of ‘conditional independence’ associated with indirect model‐based analyses. An example cost‐effectiveness analysis of Chronic Disease Self‐Management Programme is used to compare the different approaches. It is shown that despite using a common data set, the different analytic approaches produce differing estimates of the cost‐effectiveness of the intervention and the value of future research. The paper concludes by discussing the selection of the appropriate analytic approach. Copyright © 2011 John Wiley & Sons, Ltd.

Date: 2012
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://doi.org/10.1002/hec.1741

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:wly:hlthec:v:21:y:2012:i:6:p:742-756

Access Statistics for this article

Health Economics is currently edited by Alan Maynard, John Hutton and Andrew Jones

More articles in Health Economics from John Wiley & Sons, Ltd.
Bibliographic data for series maintained by Wiley Content Delivery ().